Inflammatory Bowel Diseases

Skip Navigation LinksHome > January 2011 - Volume 17 - Issue 1 > Adherence to adalimumab therapy in Crohn's disease: A French...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21491
Original Clinical Articles

Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience

Billioud, Vincent MD1; Laharie, David MD, PhD2; Filippi, Jérôme MD3; Roblin, Xavier MD4; Oussalah, Abderrahim MD1; Chevaux, Jean‐Baptiste MD1; Hébuterne, Xavier MD, PhD3; Bigard, Marc‐André MD1; Peyrin‐Biroulet, Laurent MD, PhD1

Collapse Box


Background:: We evaluated adherence to adalimumab therapy in Crohn's disease (CD).

Methods:: This was an observational multicenter study conducted in four French university hospitals between April 4, 2008 and January 1, 2010. Patients were systematically asked, at each clinical visit, whether or not they delayed or missed an injection of adalimumab over the past 3 months. Patients were also asked about the reasons for their nonadherence.

Results:: Of the 108 patients analyzed, 33 (30.6%) delayed the administration of at least one injection and 16 (14.8%) missed at least one injection over the past 3 months. The main reasons for overall nonadherence were: forgetfulness (24.6%), infection (24.6%), and travel (20%). Other reasons for nonadherence were intentional nonadherence (10.8%), pharmaceutical supply issues (9.2%), side effects (7.7%), pregnancy (1.5%), and CD‐related hospitalization (1.5%). Adalimumab regimen of 40 mg every other week was a positive predictor for injection delays (P = 0.02, odds ratio [OR] = 3.76, 95% confidence interval [CI], 1.28–11.05), whereas having at least one relapse in the past 12 months was associated with fewer delays (P = 0.02, OR = 0.37, 95% CI, 0.15–0.87). [correction made here after initial online publication]. Disease duration over 90 months negatively predicted failure to inject adalimumab (P = 0.009, OR = 0.17, 95% CI, 0.05–0.64).

Conclusions:: The overall nonadherence rate for adalimumab use was 45.4%. Most of the reasons for nonadherent behaviors could be avoided. An adalimumab regimen of 40 mg every other week was negatively related to adalimumab adherence; both the occurrence of at least one relapse in the past 12 months and disease duration over 90 months were positively related to adherence. (Inflamm Bowel Dis 2011;)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.